TH MEDICAL-B

2697
43.4207.62% ( -3.580 )
Delay Closed: Nov 16, 16:08:11

Overview

TH MEDICAL-B (2697)

Guangdong True Health Medical Technology Development Co., Ltd. engages in in the research and development, manufacture and sale of surgical robots and disposabl...

Open
47.800
High
49.360
Low
43.380
Prev. Close
47.000
Volume
825.10K
Turnover
37.87M
Avg Price
45.901
Bid/Ask Ratio
99.56%
Amplitude
12.72%
52wk High
886.000
Volume Ratio
15.96
Turnover Ratio
2.31%
52wk Low
41.740
HK Mkt Cap
1.55B
Market CapHKD
1.55B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-3.03
EPSDynamic
-3.90
EPSStatic
--
BVPS
17.53
P/B
2.48
HK Shares
35.65M
Dividend YieldTTM
--
DividendTTM
--
Shares
35.65M
Min lot size
20
Currency
HKD

TH MEDICAL-B Analyst Rating

View more

Forecast & Rating

Jul 6, 2026
Price forecast
HK$448.80933.63%
Forecast & RatingBuy
1analysts
  • Strong buy0.00%
  • Buy100.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    TH Medical-B fell 7.6% to HK$43.42 in a spike-and-fade session: it touched HK$49.00 at 09:50 BJ in the morning, roughly 4.3% above the HK$47.00 prior close, then slid through the afternoon to a HK$43.38 intraday low at 15:57 and settled near the day's bottom on 814,180 shares and HK$37.4mn turnover, a 2.28% turnover rate. The move extends the unwinding of double-digit swings tied to xenotransplant and organ-perfusion headlines, with a weekly recap pointing to fading intraday spikes, while a joint company secretary appointment read as routine governance. Fundamentals show revenue and losses expanding together: Q2 2026 revenue of HK$3.28mn was up more than 33x year on year, yet the net loss widened 12.3% to HK$34.9mn at a -1065% net margin, leaving PE at -14.33 and PB at 2.48. The stock is down 89.1% year to date, 95.1% below its HK$886 52-week high and still under its MA20 of HK$49.77, though it now sits only 4.0% above the HK$41.74 52-week low.

  2. Nov, 13

    TH Medical-B spiked and reversed: it touched HK$61.45 at 09:48 BJ, more than 17% above the prior close of HK$52.40, then slid to close at the session low of HK$47.00, down 10.3% on 10.54% turnover. This extends a pattern already visible this month, with headlines on gene-edited pig liver and organ perfusion work driving a 13.02% single-day jump, but with the perfusion technology still awaiting approval and commercialization doubts building, the stock gave back 20.74% in one session. Q2 revenue of HK$3.275 million, up more than 33-fold year on year, still came with a net loss of HK$34.9 million, EPS of -HK$1.087 and a net margin of -1065%. Year to date the shares are down 88.25%, 94.7% below the 52-week high of HK$886, under the HK$50.72 MA20 and only 12.6% above the 2 November low of HK$41.74, though pipeline progress and the joint company secretary appointment remain items to watch.

  3. Nov, 12

    TH Medical-B (2697.HK) closed up 11.17% at HK$52.25, carving a dip-then-rally profile: the morning session bottomed at HK$45.26 before a one-way afternoon climb to HK$52.50, on 1.88 million shares and HK$92.3 million turnover, a 5.26% turnover rate, supported by renewed attention on Hong Kong small-cap medtech and discussion of its organ perfusion system. Fundamentals remain pre-commercial: Q2 2026 revenue of HK$3.28 million was up roughly 33.6x year on year, yet the net loss widened 12.27% to HK$34.9 million, with PE at -17.25x and PB at 2.98x. The stock has just reclaimed its MA20 of HK$51.44 but sits far below MA60 of HK$275.7, down 86.94% year to date, 94.1% below the 12 August high of HK$886 and only 25.18% above the 2 November low of HK$41.74. Though scepticism over the pace of commercialization has repeatedly hit the shares, including a single-day fall of more than 20%.

  4. Nov, 6

    After a 12% jump the prior session, profit-taking produced a spike-and-fade session, with the shares closing down 5.7% at HK$46.52 after touching HK$50.45 at 09:42 BJ and sliding to HK$46.04 by 11:05 BJ. The organ-perfusion catalyst behind the earlier rebound, preclinical completion of ex-vivo perfusion support using six gene-edited pig livers, has been absorbed, while the passing of a joint company secretary added uncertainty. Fundamentals show revenue off a tiny base with widening losses: Q2 2026 revenue of HK$3.28 million, up more than 33x year on year, yet net loss widened 12.27% to HK$34.9 million, EPS -HK$1.087, with PB 2.65x and a negative PE. Price positioning remains weak: down 88.37% year to date, 94.75% below the 12 August 52-week high of HK$886, and only 11.45% above the 2 November low of HK$41.74. Still, the puncture and ablation robotics pipeline remains one of its few differentiated assets.

  5. Nov, 5

    2697.HK fell 5.1% to HK$49.40 after a 12% rise in the prior session, with the stock opening at HK$51.95, reaching HK$52.45 in the morning session, then sliding to a HK$48.38 afternoon low before closing at HK$49.40. The move extends a volatile rebound from the HK$41.74 52-week low set on 2 November, where organ-perfusion system news had triggered double-digit single-day gains; the shares are still 94.4% below the HK$886 52-week high, down 87.7% year-to-date, and well under the MA20 of HK$74.5 and MA60 of HK$339.1. Q2 2026 revenue was only HK$3.275 million, up 3,355% year-on-year, while net loss reached HK$34.90 million, net margin was -1,065%, EPS was -HK$1.087 and ROE -22.26%, leaving revenue growth and losses moving together. Though the stock remains 18.2% above its November low, price action is still sensitive to news flow.

News